Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised

Published on 6 Nov 2024 on Zacks

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.

Read the rest of the article

Start tracking your investments with Statfolio

We recently published a list of 8 Most Undervalued Pot Stocks to Buy According to Analysts. In th...

Insider Monkey · via Yahoo Finance 28 Nov 2024

A month has gone by since the last earnings report for Quest Diagnostics (DGX). Shares have added...

Zacks · via Yahoo Finance 21 Nov 2024

Inogen's overall third-quarter 2024 results continue to gain from higher business-to-business sal...

Zacks 10 Nov 2024

AMN Healthcare's dismal results in the majority of its segments led to a soft overall third-quart...

Zacks 8 Nov 2024

BD's overall topline in the fourth quarter of fiscal 2024 benefits from revenue growth in all...

Zacks 7 Nov 2024

Clover Health's third-quarter 2024 results continue to benefit from the strength of its business...

Zacks 7 Nov 2024

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.

Zacks 6 Nov 2024

Free Report) delivered an earnings per share (EPS) of 60 cents in third-quarter 2024 against the...

Zacks 4 Nov 2024

Fiduciary Management Inc. (FMI), an independent money management firm, released its second quarte...

Insider Monkey · via Yahoo Finance 23 Jul 2024

Quest Diagnostics (NYSE:DGX) has had a great run on the share market with its stock up by a signi...

Simply Wall St. via Yahoo Finance 23 May 2024